Zhejiang Tianyu Pharmaceutical Co., Ltd. (SHE:300702)
China · Delayed Price · Currency is CNY 23.50
+0.12 (0.51%)
At close: Feb 3, 2026
SHE:300702 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,970 | 2,615 | 2,521 | 2,651 | 2,529 | 2,586 |
Other Revenue | 15.64 | 15.64 | 6.74 | 15.33 | 16.49 | 1.37 |
| 2,986 | 2,631 | 2,527 | 2,667 | 2,545 | 2,587 | |
Revenue Growth (YoY) | 15.07% | 4.10% | -5.23% | 4.78% | -1.64% | 22.59% |
Cost of Revenue | 1,906 | 1,761 | 1,677 | 2,076 | 1,638 | 1,297 |
Gross Profit | 1,080 | 869.86 | 849.83 | 591.07 | 907.42 | 1,290 |
Selling, General & Admin | 552.54 | 500.32 | 425.45 | 423.79 | 465.02 | 361.41 |
Research & Development | 238.15 | 238.9 | 243.82 | 231.1 | 227.4 | 179.07 |
Other Operating Expenses | 30.89 | 20.91 | 28.17 | 19.72 | 24.14 | 26.16 |
Operating Expenses | 827.15 | 758.76 | 703.74 | 670.74 | 721.58 | 571.01 |
Operating Income | 252.41 | 111.1 | 146.09 | -79.67 | 185.84 | 719.41 |
Interest Expense | -46.71 | -54.07 | -49.91 | -33.85 | -16.33 | -4.41 |
Interest & Investment Income | 9.35 | 19.88 | 6.07 | 7.22 | 75.73 | 29.84 |
Currency Exchange Gain (Loss) | 25.18 | 25.18 | 8.83 | 37.92 | -10.58 | -36.24 |
Other Non Operating Income (Expenses) | -9.67 | -4.85 | -2.3 | -1.28 | -1.12 | -1.18 |
EBT Excluding Unusual Items | 230.56 | 97.24 | 108.78 | -69.66 | 233.55 | 707.42 |
Gain (Loss) on Sale of Investments | -5.39 | -30.4 | -62.69 | -59.65 | -12.97 | 42.64 |
Gain (Loss) on Sale of Assets | 0.29 | 0.72 | -0.03 | -0.02 | 0.06 | 0.21 |
Asset Writedown | -46.16 | -2.67 | -2.09 | -8.21 | -16.09 | -5.51 |
Other Unusual Items | 27.61 | 13.75 | 27.64 | 26.76 | 13.85 | 24.13 |
Pretax Income | 206.91 | 78.64 | 71.92 | -110.5 | 218.41 | 768.88 |
Income Tax Expense | 15.16 | 22.7 | 44.56 | 8.37 | 13.73 | 101.82 |
Net Income | 191.75 | 55.94 | 27.36 | -118.87 | 204.68 | 667.06 |
Net Income to Common | 191.75 | 55.94 | 27.36 | -118.87 | 204.68 | 667.06 |
Net Income Growth | 339.02% | 104.45% | - | - | -69.32% | 13.89% |
Shares Outstanding (Basic) | 347 | 350 | 342 | 350 | 347 | 324 |
Shares Outstanding (Diluted) | 347 | 350 | 342 | 350 | 347 | 325 |
Shares Change (YoY) | -0.96% | 2.22% | -2.18% | 0.78% | 6.61% | -0.62% |
EPS (Basic) | 0.55 | 0.16 | 0.08 | -0.34 | 0.59 | 2.06 |
EPS (Diluted) | 0.55 | 0.16 | 0.08 | -0.34 | 0.59 | 2.05 |
EPS Growth | 343.28% | 100.00% | - | - | -71.22% | 14.60% |
Free Cash Flow | -29.37 | 175.69 | -360.71 | -575.71 | -998.62 | 116.13 |
Free Cash Flow Per Share | -0.09 | 0.50 | -1.05 | -1.65 | -2.88 | 0.36 |
Dividend Per Share | 0.050 | 0.050 | 0.050 | - | 0.100 | 0.278 |
Dividend Growth | - | - | - | - | -64.00% | - |
Gross Margin | 36.16% | 33.06% | 33.63% | 22.17% | 35.66% | 49.87% |
Operating Margin | 8.45% | 4.22% | 5.78% | -2.99% | 7.30% | 27.80% |
Profit Margin | 6.42% | 2.13% | 1.08% | -4.46% | 8.04% | 25.78% |
Free Cash Flow Margin | -0.98% | 6.68% | -14.27% | -21.59% | -39.24% | 4.49% |
EBITDA | 594.62 | 432.5 | 439.74 | 164.56 | 371.04 | 855.5 |
EBITDA Margin | 19.92% | 16.44% | 17.40% | 6.17% | 14.58% | 33.06% |
D&A For EBITDA | 342.21 | 321.4 | 293.65 | 244.23 | 185.2 | 136.1 |
EBIT | 252.41 | 111.1 | 146.09 | -79.67 | 185.84 | 719.41 |
EBIT Margin | 8.45% | 4.22% | 5.78% | -2.99% | 7.30% | 27.80% |
Effective Tax Rate | 7.32% | 28.87% | 61.96% | - | 6.29% | 13.24% |
Revenue as Reported | 2,986 | 2,631 | 2,527 | 2,667 | 2,545 | 2,587 |
Advertising Expenses | - | 61.43 | 67.59 | 12.92 | 0.97 | 0.87 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.